Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | CDC25B | P30305 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | ELANE | P08246 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | BCL2 | P10415 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28691954 | 0.79 | PTPRC (0.39) | MEN1KMT2ACDC25BNPC1RAB9A | |
| Anthraquinone SCHEMBL28260408 | 0.79 | MEN1 (0.92) | MEN1KMT2ACDC25BNPC1RAB9A | |
| Anthraquinone SCHEMBL28141482 | 0.76 | MEN1 (0.86) | MEN1KMT2ACDC25BNPC1RAB9A | |
| Anthraquinone SCHEMBL4283294 | 0.76 | MEN1 (0.86) | MEN1KMT2ACDC25BNPC1RAB9A | |
| Anthraquinone SCHEMBL29358690 | 0.76 | MEN1 (1.00) | MEN1KMT2ACDC25BNPC1RAB9A | |
| Anthraquinone SCHEMBL14943 | 0.76 | MEN1 (1.00) | MEN1KMT2ACDC25BNPC1RAB9A | |
| Anthraquinone SCHEMBL1901249 | 0.76 | MEN1 (1.00) | MEN1KMT2ACDC25BNPC1RAB9A | |
| SCHEMBL28863139 | 0.75 | NPC1 (0.68) | MEN1KMT2ACDC25BNPC1RAB9A | |
| Anthraquinone SCHEMBL21834979 | 0.73 | MEN1 (0.80) | MEN1KMT2ACDC25BNPC1RAB9A | |
| Anthraquinone SCHEMBL20299926 | 0.73 | MEN1 (0.92) | MEN1KMT2ACDC25BNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005100482-A1 | COMPOSITIONS BASED ON SILANE-TERMINATED POLYMERS AND HARDENED BY RADIATION AND HUMIDITY, PRODUCTION AND USE THEREOF | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2005-10-27 | — | — | WO | claimed |
| US-11180523-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | QUANTUMDX GROUP LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-10759824-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | QUANTUMDX GROUP LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-10646416-B2 | Microcapsules containing a gas-releasing photolabile compound and uses thereof | FIRMENICH SA (CH) | 2020-05-12 | — | — | US | disclosed |
| US-20190248827-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| US-10273261-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | QUANTUMDX GROUP LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20190004055-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2019-01-03 | — | — | US | disclosed |
| EP-3400444-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QuantuMDx Group Limited (GB) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017120148-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2017-07-13 | — | — | WO | disclosed |
| US-20160139133-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2016-05-19 | — | — | US | disclosed |
| EP-2241551-A1 | METHOD FOR PRODUCING CYCLOPROPANE CARBOXYLIC ACID COMPOUND AND INTERMEDIATE THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20070249822-A1 | Photolabile Coumarinylmethyl Esters of Cyclic Nucleotides, Methods for their Preparation and Their Use | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2007-10-25 | — | — | US | disclosed |
| US-7138538-B2 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY (SOCIETE ANONYME) (BE) | 2006-11-21 | — | — | US | disclosed |
| EP-1276749-B1 | PHOTO-LABILE COUMARINYLMETHYL ESTERS OF CYCLIC NUCLEOTIDES, METHOD FOR THE PRODUCTION AND USE THEREOF | FORSCHUNGSVERBUND BERLIN EV (DE) | 2005-08-24 | — | — | EP | disclosed |
| US-20040210060-A1 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY S.A. (BE) | 2004-10-21 | — | — | US | disclosed |
| US-6743373-B1 | REAGENT BASED ON ENANTIOPURE AMINO ACID IN WHICH AMINO GROUP CARRIES ACTIVATING GROUP TO FORM ACTIVE PRECURSOR OF ISOCYANATE GROUP AND CARBOXYL GROUP IS SUBSTITUTED; SEPARATION OF ENANTIOMERS HAVING FREE FUNCTIONAL GROUP | SOLVAY (SOCIETE ANONYME) (BE) | 2004-06-01 | — | — | US | disclosed |
| EP-1276749-A1 | NOVEL, PHOTO-LABILE CUMARINYLMETHYL ESTERS OF CYCLIC NUCLEOTIDES, METHOD FOR THE PRODUCTION AND USE THEREOF | Forschungsverbund Berlin e.V. (DE) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001081360-A1 | NOVEL, PHOTO-LABILE CUMARINYLMETHYL ESTERS OF CYCLIC NUCLEOTIDES, METHOD FOR THE PRODUCTION AND USE THEREOF | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2001-11-01 | — | — | WO | disclosed |
| EP-0853628-A1 | PHOTOLABILE 8-SUBSTITUTED CYCLIC NUCLEOTIDE ESTERS, METHODS OF PREPARING THEM AND THEIR USE | Forschungsverbund Berlin e.V. (DE) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997005155-A1 | PHOTOLABILE 8-SUBSTITUTED CYCLIC NUCLEOTIDE ESTERS, METHODS OF PREPARING THEM AND THEIR USE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10646416-B2 | Microcapsules containing a gas-releasing photolabile compound and uses thereof | ALOX5, TRPA1, FASN | MEN1 2724/4885KMT2A 4780/4885CDC25B 151/4885 |
| US-11180523-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | POLM, RNGTT, TYMP | MEN1 2830/4885KMT2A 1303/4885CDC25B 1341/4885 |
| US-20070249822-A1 | Photolabile Coumarinylmethyl Esters of Cyclic Nucleotides, Methods for their Preparation and Their Use | HCCS, NUDT1, CBR3 | MEN1 2812/4885KMT2A 4838/4885CDC25B 272/4885 |
| US-20190004055-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | POLM, RNGTT, TYMP | MEN1 2830/4885KMT2A 1303/4885CDC25B 1341/4885 |
| US-20040210060-A1 | Process for the separation of enantiomers and enantiopure reagent | DNPEP, DAO, ANPEP | MEN1 3328/4885KMT2A 3108/4885CDC25B 2091/4885 |
| US-10759824-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | POLM, RNGTT, TYMP | MEN1 2830/4885KMT2A 1303/4885CDC25B 1341/4885 |
| US-20190248827-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | POLM, RNGTT, TYMP | MEN1 2830/4885KMT2A 1303/4885CDC25B 1341/4885 |
| US-10273261-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | POLM, RNGTT, TYMP | MEN1 2830/4885KMT2A 1303/4885CDC25B 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.